Raw Material Platform — The Innovation Engine of Core Biomaterials
Built upon advanced technologies including single B-cell monoclonal antibody production, protein purification, and AI-based protein structure modeling and molecular target simulation, Microprofit has established standardized processes for protein expression from low to high abundance, independently developing core materials such as antibodies and recombinant proteins:
- Eliminates import dependence, enabling self-sufficiency in reagents for respiratory, reproductive, and neurological disease detection;
- Enhances the stability and immune sensitivity of antigen, antibody, and recombinant protein materials;
- Builds an efficient and consistent raw material production system, providing the industry with high-quality core biomaterials.
